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In the present study aortic murine smooth muscle cell (SMC) antigen presentation capacity was evaluated using the E𝛼-GFP/Y-
Ae system to visualize antigen uptake through a GFP tag and tracking of E𝛼 peptide/MHCII presentation using the Y-Ae Ab.
Stimulation with IFN-𝛾 (100 ng/mL) for 72 h caused a significant (𝑃 < 0.01) increase in the percentage of MHC class II positive
SMCs, compared with unstimulated cells. Treatment with E𝛼-GFP (100 𝜇g/mL) for 48 h induced a significant (𝑃 < 0.05) increase
in the percentage of GFP positive SMCs while it did not affect the percentage of Y-Ae positive cells, being indicative of antigen
uptake without its presentation in the context ofMHC class II. After IFN-𝛾-stimulation, ovalbumin- (OVA, 1mg/mL) orOVA
323−339
peptide-(0.5 𝜇g/mL) treated SMCs failed to induce OT-II CD4+ T cell activation/proliferation; this was also accompanied by a lack
of expression of key costimulatory molecules (OX40L, CD40, CD70, and CD86) on SMCs. Finally, OVA-treated SMCs failed to
induce DO11.10-GFP hybridoma activation, a process independent of costimulation. Our results demonstrate that while murine
primary aortic SMCs express MHC class II and can acquire exogenous antigens, they fail to activate T cells through a failure in
antigen presentation and a lack of costimulatory molecule expression.
1. Introduction
Atherosclerosis is an immunoinflammatory process [1, 2] in
which smooth muscle cells (SMCs) play a critical role [3–
5]. SMCs produce a broad range of immunoinflammatory
mediators contributing to vascular inflammation [6] and
participate in the formation of arterial tertiary lymphoid
tissue in experimental atherosclerosis [7]. Human SMCs
express class II major histocompatibility complex molecules
(MHC class II) in atherosclerotic plaques [8] and following
IFN-𝛾 stimulation [9–11]. In addition, SMC MHC class
II expression increases following vascular injury in rodent
models [12]. However, the possibility that SMCs can act as
antigen presenting cells (APCs) and consequently activate
vascular T cell response remains, to date, controversial.
In mice it has been demonstrated that brain microvessel
SMCs/pericytes can induce a proliferation of syngenic CD4+
T cells in vitro in a MHC class II dependent manner [13].
SMCs/pericytes were able to process and present exogenous
antigens to T cell hybridoma [14] and preferentially activated
Th1 T cell clones as compared with Th2 T cells of the same
antigen specificity [15]. In contrast to syngeneic cocultures
using wild type CD4+ T cells, microvascular SMCs did not
support proliferation of antigen specific T cell receptor (TCR)
transgenic CD4+ T cells [16]. Others demonstrated that
murine SMCs pulsed with antigen increased the expression




Volume 2014, Article ID 949845, 10 pages
http://dx.doi.org/10.1155/2014/949845
2 BioMed Research International
Human saphenous vein SMCs expressing MHC class II
molecules were unable to activate allogeneic memory T cells
[18] and failed to effectively support T cell proliferation to the
polyclonal activator, phytohemagglutinin [19]. This inability
resulted from a defect in costimulatory function, particularly
the lack of OX40 ligand (OX40L) [19]. SMCs from different
tissues may behave differently; for example, cultured human
airway smooth muscle cells were capable of presenting the
superantigen, staphylococcal enterotoxin A, viaMHC class II
molecules to CD4+ T cells [20].More selective approaches are
required to investigate SMC antigen presentation capacity.
Here we utilized the E𝛼-GFP/Y-Ae model that allows
visualization of antigen uptake through a GFP tagged E𝛼
peptide and tracking of antigen presentation using the Y-
Ae Ab. The E𝛼-GFP protein is internalized and processed by
APCs to generate E𝛼 peptide for presentation on MHC class
II. The monoclonal Ab Y-Ae detects E𝛼 only when bound
to MHC class II molecules (I-Ab) [21–24]. We demonstrate
that while murine primary aortic SMCs express MHC class
II and can acquire exogenous antigens, they fail to activate T
cells through a failure in antigen presentation and a lack of
costimulatory molecule expression.
2. Materials and Methods
2.1. Animals. C57BL/6 mice (Harlan, Shardlow, UK) were
used to prepare SMCs and dendritic cells (DCs). OT-II
(CD45.1) mice bred in house were used as donors of Tg
T cells. These transgenic mice express the mouse alpha-
chain and beta-chain T cell receptor that pairs with the CD4
coreceptor and is specific for chicken ovalbumin 323–339 in
the context of I-Ab. Animals weremaintained on a 12/12-hour
light/dark cycle with free access to food and water and all the
procedures were performed in accordance with local ethical
and UK Home Office regulations.
2.2. Cell Cultures and Cocultures. Murine primary SMCs
were derived from the thoracic aorta of C57BL/6 mice
as previously described [25, 26] and grown in DMEM
supplemented with L-glutamine, 10% fetal bovine serum,
100U/mL penicillin, and 100 𝜇g/mL streptomycin (all from
Gibco, Paisley, UK). Before initiation of the assays, the SMCs
were starved into DMEM supplemented with 0.1% fetal
bovine serum for 48 hours [25, 27]. Cells were character-
ized by immunofluorescence microscopy using FITC labeled
anti-smooth muscle 𝛼-actin (𝛼-SMA) monoclonal antibody
(Ab) (clone 1A4; Sigma-Aldrich, Dorset, UK). Studies were
performed with cells at passages 3–6. OVA specific TCR
transgenic OT-II CD4+ T cells were isolated from OT-
II/CD45.1 mice using the MicroBead-based CD4+ T Cell
Isolation Kit II (Miltenyi Biotec, Bisley, UK) according to
manufacturer’s instructions and grown in complete RPMI
(containing L-glutamine, 10% fetal bovine serum, 100U/mL
penicillin, and 100 𝜇g/mL streptomycin). The DO11.10-GFP
hybridoma cells [28] were grown in complete RPMI con-
taining geneticin (0.5mg/mL, Sigma-Aldrich) as previously
described [29]. DCs were obtained by flushing the bone
marrow of C57BL/6 mice and grown in complete RPMI
containing 10% granulocyte-macrophage colony stimulating
factor (GM-CSF) for 7 days [30]. All cells used were kept in a
humidified incubator at 37∘C in 5% CO
2
.
Murine SMCs were cultured in 48 multiwell plates until
80% confluence. Subsequently cells were stimulated with
IFN-𝛾 (100 ng/mL; R&D Systems, Abingdon, UK) for 72 h to
enhance their MHC class II expression and then treated with
OVA (1mg/mL; InvivoGen, Toulouse, France) or OVA
323−339
peptide (0.5 𝜇g/mL; InvivoGen) overnight. Isolated OT-II
CD4+ T cell or DO11.10-GFP hybridoma cell preparations
were then introduced into the murine SMC cultures at a
1 : 5 ratio, for 24, 48, and 72 h or 24 h, respectively. OVA-
treated DCs, cocultured with both OT-II CD4+ T cells and
DO11.10-GFPhybridoma cells at the same ratio of SMCs,were
used as positive control. Subsequently, OT-II CD4+T cells or
DO11.10-GFP hybridoma cells were collected by rinsing the
cocultures three times followed by staining and preparation
for flow cytometric analysis. For the analysis of costimula-
tory molecule expression murine SMCs were cultured in 6
multiwell plates and stimulated with IFN-𝛾 (100 ng/mL) for
72 h before flow cytometry. In a separate set of experiments,
SMCs were stimulated with IFN-𝛾 (100 ng/mL) for 72 h and
then treated with fluorescein labeled-chicken OVA (FITC-
OVA, 1mg/mL, Molecular Probes) overnight. Subsequently,
the supernatant was removed and the cells washed with PBS.
TheFITC-OVAuptakewas visualized using the EVOSFLCell
Imaging System (Life Technologies Ltd., Paisley, UK).
2.3. Ealpha-GFP Preparation and Treatment. To assess the
ability of murine SMCs to act as APCs, we employed the
Ealpha- (E𝛼-) GFP/Y-Ae system as previously described [22–
24]. A recombinant Escherichia coli strain expressing the E𝛼-
GFP fusion protein was grown tomidlog phase before induc-
tion of protein expression. Protein expression was induced
by addition of isopropyl 𝛽-D-1-thiogalactopyranoside (IPTG;
Sigma-Aldrich) to a final concentration of 1mM and cultures
were incubated overnight at 30∘C with agitation (200 rpm).
The E𝛼-GFP fusion protein was purified from the bacterial
lysates using HisPur Cobalt Spin Columns (Thermo Sci-
entific, Loughborough, UK) and endotoxin was removed
using Detoxi-Gel Endotoxin Removing Columns (Thermo
Scientific). Murine SMCs were cultured in 6 multiwell plates,
as described above, stimulated with IFN-𝛾 (100 ng/mL) for
72 h, and then treated with E𝛼-GFP (100 𝜇g/mL). After 1, 24,
and 48 h of treatment, cells were collected for flow cytometric
analysis. DCs cultured under the same conditions and treated
with E𝛼-GFP (100𝜇g/mL) for 24 h were used as a positive
control.
2.4. Flow Cytometry. Aliquots of cells were washed and
resuspended in Fc block (2.4G2 hybridoma supernatant) for
25mins at 4∘C to block Fc receptors. Subsequently, cells
were incubated with Abs (in PBS containing 2% FBS) for
30mins at 4∘C, washed twice and then, where necessary,
incubated with streptavidin for additional 20mins at 4∘C.
Following washing, cells were analyzed on a FACScalibur
using CellQuest-Pro (BD Biosciences, Oxford, UK), or on
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a MACSQuant Analyzer (Miltenyi Biotec). Data analysis was
performedusing 6 FlowJo (Tree Star Inc., Olten, Switzerland).
Murine SMCs were stained with the following pri-
mary Abs: Y-Ae-Bio (specific for I-E𝛼 52–68 presented on
I-Ab; clone: eBioY-Ae), anti-MHC II (I-A/I-E)-APC (clone:
M5/114.15.2), anti-CD11c-APC (clone: N418), anti-CD54-PE
(clone: 3E2), anti-CD44-FITC (clone: IM7), anti-OX40L-Bio
(clone: RM134L) followed by streptavidin-PerCP, anti-CD80-
FITC (clone: 16-10A1), anti-CD40-PE (clone: 3/23), anti-
CD86-APC (clone: GL1), and anti-CD70-Bio (clone: FR70)
followed by streptavidin-PerCP. OT-II CD4+ T cells were
stainedwith primarymAbs anti-CD4-PerCP (clone: RM4-5),
anti-CD25-APC (clone: PC61), anti-CD44-PE (clone: IM7),
and anti-CD69-Bio (clone: H1.2F3) followed by streptavidin-
Pacific Blue. DO11.10-GFP hybridoma cells were stained with
the primary Ab anti-DO11.10 TCR-APC (clone: KJ 1-26).
Isotype-matched Abs were used as negative control. Y-Ae
Ab, anti-CD11c, and anti-MHC II Ab were from eBioscience
(Hatfield, UK); streptavidin-Pacific Blue was from Life Tech-
nologies Ltd.; all other Abs were from BD Biosciences.
2.5. CFSE Staining. OT-II CD4+ T cells were labeled with
the fluorescent dye carboxyl fluorescein succinimidyl ester
(CFSE, Molecular Probes) as previously described [31]. The
cells were washed and then cocultured with SMCs or DCs
(used as a positive control) for 72 h. The level of fluores-
cence intensity from the CFSE labeling was measured by
flow cytometry. Incremental loss of CFSE intensity showed
proliferation.
2.6. Statistical Analysis. Results are expressed asmean± SEM
of 3 experiments run in triplicate.The results were statistically
analyzed by the 𝑡-test or ANOVA (Two-Tail 𝑃 value) and the
Bonferroni post hoc test. The level of statistical significance
was 𝑃 < 0.05 per test.
3. Results
3.1. Assessment of Antigen Uptake/Presentation by SMCs
Using the E𝛼-GFP/Y-Ae System. Stimulation with IFN-𝛾
(100 ng/mL) for 72 h resulted in a significant (𝑃 < 0.01) 5-
to 6-fold increase in the percentage of MHC class II pos-
itive SMCs compared with unstimulated cells (Figure 1(a)).
Similar results were observed in IFN-𝛾-stimulated SMCs
subsequently treated with E𝛼 peptide (100 𝜇g/mL) for 1 and
24 h (𝑃 < 0.05), while no significant changes were observed
after 48 h of treatment (Figure 1(a)). As shown in Figure 1(b),
SMC treatment with E𝛼 peptide induced an increase in the
percentage of GFP positive cells, both in presence or absence
of IFN-𝛾-stimulation, being indicative of antigen uptake.The
increase in GFP positive cells observed was significant only
at 48 h (𝑃 < 0.05). No significant changes were observed in
the percentage of Y-Ae positive SMCs after IFN-𝛾-stimulation
and/or treatment with E𝛼 peptide (Figure 1(c)) suggesting
that, although SMCs internalize the antigen, they are not
able to present the E𝛼 peptide in the context of MHC class
II. Treatment of DCs with E𝛼 peptide (100 𝜇g/mL), used as
positive control, caused an increase in the percentage of Y-Ae
positive cells (Figure 1(d)).
3.2. SMCs Fail to Induce OT-II CD4+ T Cell Activation
and Proliferation. We next assessed the ability of SMCs to
activateOVA-specific transgenicCD4+ Tcells. In preliminary
experiments by using FITC-OVAwe confirmed the uptake of
the model antigen by SMCs (data not shown). Using CFSE
to track proliferation, we evaluated the number of Tg T cells
undergoing proliferation after 72 h of coculture with SMCs or
bone marrow derived DCs, used as positive control.The pro-
portion of dividing T cells (expressed as percentage of CFSE−
CD4+ cells) was approximately 0.5–1% in both presence
and absence of cocultured unstimulated SMCs (Figure 2).
Neither stimulation with IFN-𝛾 nor treatment with OVA or
OVA
323−339
peptide of SMCs affected the proliferation of OT-
II CD4+ T cells. In contrast, coculture with OVA-treated DCs
significantly (𝑃 < 0.01) increased the proportion of dividing
OT-II CD4+T cells by around 20% (Figure 2).
We also examined cell surface expression of activation
markers such as CD25, CD44, and CD69 on OT-II CD4+
T cells after coculture with SMCs or bone marrow derived
DCs. CD25 and CD69 were detected in approximately 2% of
OT-II CD4+ T cells, alone or cocultured for 24, 48, and 72 h
with unstimulated SMCs, IFN-𝛾-stimulated SMCs, or IFN-
𝛾-stimulated SMCs treated with OVA or OVA
323−339
peptide.
Moreover, the percentage of CD25 and CD69 positive T cells
did not change after SMC treatment with OVA or OVA
323−339
peptide alone, while a significant (𝑃 < 0.001) increase was
observed only after coculture with OVA-treated DCs at all
of the time points considered (Figure 3). The percentage of
CD44 positive OT-II CD4+ T cells was about 7% at all of
the time points considered, in both presence and absence
of unstimulated SMCs. Stimulation with IFN-𝛾 and/or treat-
ment of SMCs with OVA or OVA
323−339
did not affect CD44
expression. A significant (𝑃 < 0.01) increase in CD44
positive OT-II CD4+ T cells was observed after 48 and 72 h
of coculture with OVA-treated DCs (Figure 3). These data
demonstrate that antigen-pulsed aortic murine SMCs are not
able to induce antigen-specific T cell activation/proliferation.
3.3. Effect of IFN-𝛾 Stimulation on Costimulatory/Adhesion
Molecules Expression byMurine SMCs. Previous studies have
correlated the inability of human SMCs to activate memory
T cells with the lack of costimulation [19]. Thus we exam-
ined whether murine SMCs express costimulatory/adhesion
molecules at baseline and after IFN-𝛾 (100 ng/mL) stimu-
lation for 72 h. As shown in Figure 4, unstimulated SMCs
expressed CD54 (ICAM-1), CD80, and CD44 (30%, 11%, and
87% positive cells, resp.). The stimulation with IFN-𝛾 caused
a 2-fold increase in the percentage of both ICAM-1 (𝑃 <
0.01) and CD80 (𝑃 < 0.001) positive cells while it did not
affect the percentage of CD44 positive cells. In contrast, only
low levels of OX40L, CD40, CD70, and CD86 expression
were detectable in unstimulated SMCs. IFN-𝛾 stimulation
did not increase the percentage of SMCs positive to these
molecules. The failure of SMCs to respond to IFN-𝛾, in this
case, was selective for the costimulatory molecules because
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Figure 1: SMCs acquire exogenous antigens but fail to present them in the context ofMHC class II. Evaluation of antigen uptake/presentation
by murine SMCs. SMCs were stimulated with IFN-𝛾 (100 ng/mL) for 72 h and subsequently treated with E𝛼-GFP peptide (100𝜇g/mL) for the
indicated time points. (a)MHC class II expression. (b) GFP expression. (c) Representative flow cytometry plots showing no positivity of SMCs
to the Y-Ae Ab or (d) positivity of DCs, used as a positive control. Results are expressed as mean ± SEM from three separate experiments.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, versus unstimulated cells.
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Figure 2: SMCs fail to induce OT-II CD4+ T cell proliferation. Representative plots and relative statistical analysis showing the effect of SMCs
on OT-II CD4+ T cell proliferation. IFN-𝛾-stimulated SMCs were treated with OVA (1mg/mL) or OVA
323−339
peptide (0.5𝜇g/mL) overnight
and then cocultured with CFSE-labeled OT-II CD4+ T cells for 72 h. OVA-treated DCs were used as a positive control. Results are expressed
as mean ± SEM from three separate experiments run in triplicate. ∗∗𝑃 < 0.01 versus OT-II CD4+ T cells alone.
the percentage of MHC class II molecules was increased after
IFN-𝛾 stimulation under the same conditions (Figure 4).
3.4. SMCs Do Not Activate DO11.10-GFP Hybridoma Cells.
ThemurineDO11.10-GFP hybridomawas originally obtained
by stably transfecting a DO11.10 T cell hybridoma with
a construct in which GFP expression is under the con-
trol of a nuclear factor of activated T cells (NFAT) regu-
lated promoter [28]. Thus, once activated, hybridoma cells,
detectable using the KJ1-26 clonotypic antibody, become
GFP-positive. DO11.10 hybridoma cells express the TCR
recognizing OVA
323−339
peptide in the context of either I-Ad
or I-Ab MHC class II [32] without any requirement for
costimulation [29]. Coculture with unstimulated SMCs had
no effect onGFP expression byDO11.10-GFP hybridoma cells
and similar results were obtained after stimulation with IFN-
𝛾 and/or treatment of SMCswithOVAorOVA
323−339
peptide.
On the contrary, DCs treated with OVA, used as positive
control, caused a significant (𝑃 < 0.001) increase in GFP
expression by hybridoma cells (Figure 5).These data confirm
that SMCs are unable to present exogenous protein antigens
in the context of MHC class II.
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Figure 3: SMCs fail to induce OT-II CD4+ T cell activation. Expression of CD69, CD25, and CD44 on OT-II CD4+ T cells cocultured with
OVA- or OVA
323−339
peptide-treated SMCs or OVA-treated DCs (used as positive control). Results are expressed as mean ± SEM from three
separate experiments run in triplicate. ∗∗∗𝑃 < 0.001 versus OT-II CD4+ T cells alone at 24 h; ∘∘𝑃 < 0.01, ∘∘∘𝑃 < 0.001 versus OT-II CD4+ T
cells alone at 48 h; ##𝑃 < 0.01 and ###𝑃 < 0.001 versus OT-II CD4+ T cells alone at 72 h.
4. Discussion
In the present study, we demonstrated that (1) cultured
primary murine SMCs express MHC class II molecules
after stimulation with IFN-𝛾 and are able to acquire/uptake
antigens; however, they fail to present the peptide antigen
in the context of MHC class II, as demonstrated by using
the specific Ealpha- (E𝛼-) GFP/Y-Ae system; (2) OVA-treated
SMCs fail to induce activation/proliferation of OT-II CD4+ T
cells, data consistent with a defect in MHC class II-restricted
Ag presentation and in the expression of costimulatory
molecules, such as OX40L, CD40, CD70, and CD86; (3)
SMCs also fail to promote activation of OVA responding
DO11.10-GFP hybridoma T cells that do not require any
costimulatory signal for activation.
The first finding that murine aortic SMCs express MHC
class II molecules is in line with previous data showingMHC
class II expression in atheroma SMCs [8] and in rodent
arteries in response to injury [12], as well as in human
SMCs in culture following IFN-𝛾-stimulation [18]. Murray
and colleagues [18] demonstrated that class II molecules on
human saphenous vein SMCs were functional, since they
inducedCD25 expression on restingCD4+ T cells. Additional
studies demonstrated that survival and activation of T cells
occurred as a result of the specific interaction between TCR
on T cells and MHC molecules on SMCs, since treatment
with antibodies directed toward MHC class II blocked the
proliferation of CD4+ T cells cocultured with syngeneic
SMCs [13, 16]. On the contrary, in the context of nonspecific
generalized T cell stimulation or in the presence of polyclonal
activators such as phytohemagglutinin SMCs did not activate
CD4+ T cells [18, 19].
In order to understand whether an antigen specific
stimulation leads to immunological competence of SMCs,
engaging MHC molecules, we employed a novel and selec-
tive approach such as the E𝛼-GFP/Y-Ae model that allows
visualization of antigen uptake through a GFP tagged E𝛼
peptide and tracking of antigen presentation using the Y-
Ae Ab. The E𝛼-GFP protein is internalized and processed
by APCs to generate E𝛼 peptide for presentation on MHC
class II. The monoclonal Ab Y-Ae detects E𝛼 only when
bound to MHC class II molecules (I-Ab) [21–24]. E𝛼-GFP
treatment of SMCs increased the percentage of GFP positive
cells, without affecting the percentage of SMCs positive to
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Figure 4: SMCs lack key costimulatory molecules. Representative flow cytometry histograms and relative graph showing the effect of IFN-𝛾
(100 ng/mL) on costimulatory/adhesionmolecules expression inmurine SMCs. Red empty histograms: isotype control; gray filled histograms
or white columns: unstimulated SMCs; black empty histograms or black columns: IFN-𝛾-stimulated SMCs. Results are expressed as mean ±
SEM from three separate experiments run in triplicate. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus unstimulated cells.
the monoclonal Ab Y-Ae. These results clearly demonstrate
that primary aortic murine SMCs fail to present exogenous
protein antigens in the context of MHC class II.
Our results also prove the inability of SMCs in inducing
OVA specific OT-II CD4+ T cell activation and proliferation.
Apossible explanation for these observations is that SMCs fail
to activate T cells through a failure in antigen presentation
and a lack of costimulatory molecule expression. Indeed,
although human SMCs express the costimulatory molecules
CD44, CD54, CD58, and CD59 [18], they lack OX40L,
which is considered essential for T cell activation [19]. We
also observed lack of costimulatory molecule expression
(OX40L, CD40, CD70, and CD86) on SMC surface following
IFN-𝛾 stimulation, supporting the hypothesis that impaired
costimulation function contributes to the inability of SMCs
to induce T cells activation/proliferation.
In order to analyze this point further, we cocultured SMCs
with the DO11.10-GFP hybridoma cells that, in presence of
the model Ag OVA, undergo activation without requiring
any costimulatory signal [28, 29]. Importantly, SMCs failed
to activate DO11.10-GFP hybridoma cells, demonstrating that
other mechanisms, apart from a defect in costimulation
function, are liable for the limited capacity of SMCs to activate
T cells.
One possibility could be that SMCs cannot process
protein antigens, rather than not being able to present
8 BioMed Research International
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Figure 5: Effect of SMCs on DO11.10-GFP hybridoma cell activation. IFN-𝛾-stimulated SMCs were treated with (OVA, 1mg/mL) or
OVA
323−339
peptide (0.5 𝜇g/mL) overnight and then cocultured with DO11.10-GFP hybridoma cells for 24 h. OVA-treated DCs were used
as positive control. Results are expressed as mean ± SEM from three separate experiments run in triplicate. ∗∗∗𝑃 < 0.001 versus DO11.10-GFP
hybridoma cells alone.
them. Nevertheless, in our experiments, treatment of
SMCs with OVA
323−339
peptide, which does not require
any processing to be presented in the context of MHC
molecules, did not affect activation/proliferation of
neither OT-II CD4+ T cell nor DO11.10-GFP hybridoma
cells. This observation demonstrates that the SMC
inability in presentation cannot lie in a defect in the
antigen processing; thus further investigations will be
necessary to understand the mechanisms underlining this
deficiency.
5. Conclusions
In summary, our work demonstrates that while murine
primary aortic SMCs express MHC class II and can acquire
exogenous antigens, they fail to activate T cells through
a failure in antigen presentation and a lack of costimula-
tory molecule expression. Our results do not preclude the
possibility that SMCs could act as APCs, depending on
the environment (e.g., in atherosclerotic arteries) and the
vascular bed; however, they suggest that antigen presentation
BioMed Research International 9
may not be the key immunological feature of SMCs in the
initiation of vascular inflammation.
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[7] K. Lötzer, S. Döpping, S. Connert et al., “Mouse aorta smooth
muscle cells differentiate into lymphoid tissue organizer-
like cells on combined tumor necrosis factor receptor-
1/lymphotoxin 𝛽-receptor NF-𝜅B Signaling,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 30, no. 3, pp. 395–402,
2010.
[8] G. K. Hansson, L. Jonasson, J. Holm, and L. Claesson-Welsh,
“Class II MHC antigen expression in the atheroscerotic plaque:
smoothmuscle cells expressHLA-DR,HLA-DQ and the invari-
ant gamma chain,” Clinical and Experimental Immunology, vol.
64, no. 2, pp. 261–268, 1986.
[9] S. J. C. Warner, G. B. Friedman, and P. Libby, “Regulation of
major histocompatibility gene expression in human vascular
smooth muscle cells,” Arteriosclerosis, vol. 9, no. 3, pp. 279–288,
1989.
[10] S. Stemme, G. Fager, and G. K. Hansson, “MHC class II antigen
expression in human vascular smooth muscle cells is induced
by interferon-gamma andmodulated by tumour necrosis factor
and lymphotoxin,” Immunology, vol. 69, no. 2, pp. 243–249, 1990.
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